Filing summary
Entity and period: The supplied filing is Chavant Capital Acquisition Corp.’s Form 10-K for the fiscal year ended December 31, 2022—not a 10-K filed by Mobix Labs, Inc. Chavant is a Cayman Islands SPAC with no operating business or operating revenue. It proposed combining with Mobix Labs; the combined company was expected to take the Mobix Labs, Inc. name. The financial statements compare full-year 2022 with March 19–December 31, 2021, so the prior period is shorter and not directly comparable.
Financial performance and position
| Metric | FY 2022 / Dec. 31, 2022 | Prior period / Dec. 31, 2021 |
|---|---|---|
| Operating revenue | None | None |
| Operating expenses | $1.260 million | $762,456 |
| Net income (loss) | $(776,129) | $361,059 |
| Trust investments and cash | $9.835 million | $80.003 million |
| Cash outside trust | $175,788 | $240,706 |
| Working capital | Deficit of $844,469 | Not clearly stated in the provided text |
| Current sponsor loans | $662,000 | None reported |
The 2022 net loss reflected operating costs and a $1.109 million initial fair-value loss on the PIPE derivative liability, partly offset by a $1.332 million gain from revaluing private warrant liabilities, a $43,412 PIPE derivative fair-value gain, and $217,210 of trust interest. Cash used in operating activities was $321,008. Investing activities provided $70.167 million, mainly reflecting trust withdrawals for redemptions; financing activities used $69.911 million, also principally reflecting redemptions. Margins are not meaningful because Chavant had no operating revenue.
At year-end, total assets were $10.011 million and total liabilities were $2.421 million, including a $335,240 warrant liability and $1.065 million PIPE derivative liability. Redeemable shares were recorded as temporary equity at $9.735 million. The filing reports no long-term debt or lease obligations; sponsor working-capital loans were short-term obligations.
Material changes and transaction status
- In July 2022, holders redeemed 7,046,967 shares for $70.573 million, about $10.01 per share, following an extension vote. At December 31, 2022, 953,033 public shares remained subject to possible redemption.
- On November 15, 2022, Chavant and Mobix Labs signed a business combination agreement. The proposed transaction included a fully committed $30 million PIPE at $10 per share, subject to closing conditions, including shareholder approval and SEC effectiveness of a Form S-4.
- In January 2023, shareholders extended the SPAC deadline to July 22, 2023. Holders redeemed another 96,991 shares for $1.005 million. By March 30, 2023, 856,042 public shares remained, the trust held $9.091 million, and sponsor loans drawn totaled $962,000.
- As of March 30, 2023, sponsor and other initial shareholders collectively held approximately 70% of outstanding shares, a concentration relevant to transaction voting and governance.
Outlook, risks, and unusual items
- Liquidity and going concern: Management said the $175,788 of cash outside the trust at year-end was not expected to fund operations for the next 12 months absent a business combination. The auditor highlighted substantial doubt about Chavant’s ability to continue as a going concern. Management expected the transaction and/or further sponsor loans to address funding needs, but success was not assured.
- Transaction and funding risks: The Mobix Labs transaction was not completed as of the filing. High redemptions, financing availability, closing conditions, regulatory review, and the July 22, 2023 deadline could affect completion. The filing states Mobix Labs is early-stage, with a limited operating history; it provides no operating projections in the supplied text.
- Listing risk: After year-end, Nasdaq notified Chavant that its ordinary shares had been below the $35 million minimum market value requirement for 30 consecutive business days. It had until September 19, 2023 to regain compliance or face potential delisting proceedings.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2022. Material weaknesses involved insufficient accounting expertise and controls over earnings per share, trust-interest cash-flow classification, PIPE accounting, and review of third-party valuations. Management described remediation plans, but their effectiveness was not established.
- Accounting volatility: Fair-value changes in warrant and PIPE derivative liabilities affected reported earnings. The PIPE includes make-whole shares if the post-registration VWAP falls below $10, with a $7 floor; this could create dilution.
- Other exposures: Trust assets could be subject to creditor claims, potentially reducing redemptions. Public warrants receive no liquidation distribution and may expire worthless if no business combination closes. A $2.8 million underwriter marketing fee is payable only upon a completed business combination. The filing also discusses potential Investment Company Act, tax, regulatory, and conflicts-of-interest risks.
Investor verification priorities
- Confirm the actual status and final terms of the Mobix Labs transaction, including shareholder approvals, SEC registration effectiveness, closing conditions, and any subsequent amendments or termination.
- Reconcile post-redemption trust cash, remaining public shares, sponsor extension deposits, and total sponsor loans against later SEC filings.
- Assess whether the transaction’s minimum-cash and financing requirements were met after redemptions, and quantify any additional financing or dilution.
- Review remediation of the disclosed material weaknesses and whether subsequent filings report control improvements, restatements, or accounting changes.
- Check Nasdaq listing compliance and the outcome of the notice, and evaluate redemption, warrant, and potential creditor-claim risks.